Pdb132 - Type 2 Diabetes Treatment Paths and Patient Outcomes in Response to Reimbursement Policy Change in Finland

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.837
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

New England Journal of Medicine
Medicine
2010English

Paradoxical Glycaemic Response to Surgical Treatment of Ovarian Hyperthecosis in a Patient With Type 2 Diabetes

British Journal of Diabetes and Vascular Disease
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2015English

Microvascular Outcomes in Type 2 Diabetes

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Response to Comment on «Type 2 Diabetes Mellitus – Time to Change the Concept»

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2014English

Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients With Type 2 Diabetes

Journal of Managed Care Pharmacy
2014English

Predictors of Treatment Response to Liraglutide in Type 2 Diabetes in a Real-World Setting

Acta Diabetologica
Internal MedicineMedicineDiabetesMetabolismEndocrinology
2018English

Fournier’s Gangrene in a Patient on Dapagliflozin Treatment for Type 2 Diabetes

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

The Burden of Treatment Failure in Type 2 Diabetes: Response to Brown Et Al.

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2005English

Glycemic Treatment in Type 1 and Type 2 Diabetes

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy